4.5 Article

Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels

期刊

NEUROBIOLOGY OF AGING
卷 84, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2019.05.008

关键词

TREM2; MS4A6A; Alzheimer's disease; Genome-wide association study

资金

  1. National Natural Science Foundation of China [91849126]
  2. National Key R&D Program of China [2018YFC1314700]
  3. Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]
  4. Zhangjiang Lab, Tianqiao and Chrissy Chen Institute
  5. State Key Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University
  6. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  7. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  8. National Institute on Aging
  9. AbbVie
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. Araclon Biotech
  13. BioClinica, Inc
  14. Biogen
  15. Bristol-Myers Squibb Company
  16. CereSpir, Inc
  17. Cogstate
  18. Genentech, Inc
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  23. Johnson & Johnson Pharmaceutical Research & Development LLC.
  24. Lumosity
  25. Lundbeck
  26. Merck Co, Inc
  27. Meso Scale Diagnostics, LLC.
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corporation
  31. Pfizer Inc
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Company
  35. Transition Therapeutics
  36. Canadian Institutes of Health Research
  37. French National Foundation on Alzheimer's disease and related disorders
  38. Labex DISTALZ grant
  39. Inserm
  40. Institut Pasteur de Lille
  41. Universite de Lille 2
  42. Lille University Hospital
  43. Medical Research Council [503480]
  44. Alzheimer's Research UK [503176]
  45. Wellcome Trust [082604/2/07/Z]
  46. German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) [01GI0102, 01GI0711, 01GI0420]
  47. NIH/NIA [R01 AG033193, U01 AG032984, U24 AG021886, U01 AG016976]
  48. NIA [AG081220]
  49. AGES [N01-AG-12100]
  50. NHLBI [R01 HL105756]
  51. Icelandic Heart Association
  52. Erasmus Medical Center
  53. Erasmus University
  54. Alzheimer's Association grant [ADGC-10-196728]
  55. National Institute of Biomedical Imaging and Bioengineering
  56. Eisai Inc
  57. Elan Pharmaceuticals, Inc
  58. Eli Lilly and Company
  59. EuroImmun
  60. F. Hoffmann-La Roche Ltd

向作者/读者索取更多资源

The triggering receptor expressed on myeloid cells 2 (TREM2) gene has been reported to increase the risk of Alzheimer's disease (AD). The soluble TREM2 protein (sTREM2) in cerebrospinal fluid (CSF) was also associated with AD. However, the role of sTREM2 in AD and its genetic modifiers remain unclear. We carried out a genome-wide association study for CSF sTREM2 levels using participants from the Alzheimer's Disease Neuroimaging Initiative and validated the significant association in an independent cohort from Chinese Alzheimer's Biomarker and LifestylE study. rs7232 in membrane spanning 4-domains A6A (MS4A6A) gene was associated with CSF sTREM2 levels at genome-wide significance (p = 1.42 x 10(-15)). The locus influences CSF sTREM2 levels especially in nondemented individuals. And the association was replicable in the validation cohort from Chinese Alzheimer's Biomarker and LifestylE study (p = 0.0106). Besides, the expressions of MS4A6A and TREM2 were correlated in brain regions (p < 2 x 10(-16)). The findings of our study suggest that the AD risk variant in the MS4A6A gene participates in the regulation of sTREM2. (C) 2019 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据